Skip to main
STOK
STOK logo

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 25%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics has established a promising outlook due to its innovative TANGO approach and the significant progress of its lead program, zorevunersen, which demonstrates substantial potential in treating Dravet syndrome. The recent collaboration with Biogen not only validates zorevunersen's drug profile and enhances commercialization prospects but also alleviates financial pressures by sharing development costs, boosting the confidence in the drug's success. Additionally, the robust clinical data showing sustained seizure reduction and improvements across various behavioral measures further underpins the company's growth potential, providing a strong foundation for future financial performance.

Bears say

Stoke Therapeutics Inc faces significant financial and operational risks that contribute to a negative outlook on its stock. The company may encounter challenges related to key patent protections, which could undermine its market success and lead to valuation declines. Additionally, substantial uncertainties surrounding the clinical development and commercialization of its drug candidates, along with the necessity of raising additional capital, further exacerbate the risks of investment in the company.

STOK has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 25% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Buy based on their latest research and market trends.

According to 12 analysts, STOK has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.